Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9046014rdf:typepubmed:Citationlld:pubmed
pubmed-article:9046014lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0025914lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0599851lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0282151lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:9046014lifeskim:mentionsumls-concept:C0205341lld:lifeskim
pubmed-article:9046014pubmed:issue2lld:pubmed
pubmed-article:9046014pubmed:dateCreated1997-5-27lld:pubmed
pubmed-article:9046014pubmed:abstractTextIn vivo effects of single and repeated interferon-alpha administrations on the dynamics of noradrenaline, dopamine and 5-hydroxytryptamine were investigated in the mouse brain. Single interferon-alpha administration (15, 30 and 60 X 10(6) U/kg i.p.) had no significant effect on the levels of monoamines and their metabolites or monoamine turnover. When interferon-alpha (15 X 10(6) U/kg i.p.) was administered once a day for 5 days, however, both dopamine and 3,4-dihydroxyphenylacetic acid levels were significantly decreased and alpha-methyl-p-tyrosine-induced dopamine depletion was significantly suppressed. These results suggest that repeated interferon-alpha administration inhibits dopaminergic neural activity. This inhibitory action of interferon-alpha in dopamine neurons may be involved in adverse central effects, such as parkinsonism and depression with suicidal potential.lld:pubmed
pubmed-article:9046014pubmed:languageenglld:pubmed
pubmed-article:9046014pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9046014pubmed:citationSubsetIMlld:pubmed
pubmed-article:9046014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9046014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9046014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9046014pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9046014pubmed:statusMEDLINElld:pubmed
pubmed-article:9046014pubmed:monthFeblld:pubmed
pubmed-article:9046014pubmed:issn0006-8993lld:pubmed
pubmed-article:9046014pubmed:authorpubmed-author:HorikawaTTlld:pubmed
pubmed-article:9046014pubmed:authorpubmed-author:KataokaYYlld:pubmed
pubmed-article:9046014pubmed:authorpubmed-author:OishiRRlld:pubmed
pubmed-article:9046014pubmed:authorpubmed-author:ShutoHHlld:pubmed
pubmed-article:9046014pubmed:authorpubmed-author:FujiharaNNlld:pubmed
pubmed-article:9046014pubmed:issnTypePrintlld:pubmed
pubmed-article:9046014pubmed:day7lld:pubmed
pubmed-article:9046014pubmed:volume747lld:pubmed
pubmed-article:9046014pubmed:ownerNLMlld:pubmed
pubmed-article:9046014pubmed:authorsCompleteYlld:pubmed
pubmed-article:9046014pubmed:pagination348-51lld:pubmed
pubmed-article:9046014pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:meshHeadingpubmed-meshheading:9046014-...lld:pubmed
pubmed-article:9046014pubmed:year1997lld:pubmed
pubmed-article:9046014pubmed:articleTitleRepeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain.lld:pubmed
pubmed-article:9046014pubmed:affiliationDepartment of Hospital Pharmacy, Faculty of Medicine, Kyushu University, Fukuoka, Japan.lld:pubmed
pubmed-article:9046014pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9046014lld:pubmed